Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial - 20/06/20
, Helen M Colhoun, ProfMD d, Rafael Diaz, MD e, Luis-Emilio García-Pérez, MD f, Mark Lakshmanan, MD f, Angelyn Bethel, MD f, Denis Xavier, ProfMD g, Jeffrey Probstfield, ProfMD h, Matthew C Riddle, ProfMD i, Lars Rydén, ProfMD j, Charles Messan Atisso, PhD f, Stephanie Hall, BA c, Purnima Rao-Melacini, MSc c, Jan Basile, ProfMD k, William C Cushman, MD l, Edward Franek, ProfMD m, Matyas Keltai, ProfMD n, Fernando Lanas, ProfPhD o, Lawrence A Leiter, ProfMD p, Patricio Lopez-Jaramillo, ProfPhD q, Valdis Pirags, ProfMD r, Nana Pogosova, ProfMD s, Peter J Raubenheimer, MBBCh t, Jonathan E Shaw, ProfMD u, Wayne H-H Sheu, ProfMD v, Theodora Temelkova-Kurktschiev, ProfPhD wSummary |
Background |
Diabetes is an independent risk factor for cognitive impairment. We aimed to investigate the association between the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide and cognitive impairment as an exploratory analysis within the Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial.
Methods |
REWIND is a randomised, double-blind placebo-controlled trial at 371 sites in 24 countries. We included men and women (aged ≥50 years) with either established or newly diagnosed type 2 diabetes and additional cardiovascular risk factors, glycated haemoglobin of up to 9·5% (80 mmol/mol) on a maximum of two oral glucose-lowering drugs with or without basal insulin, and a body-mass index of at least 23 kg/m2. Participants were randomly assigned (1:1) subcutaneous injections once a week of either dulaglutide (1·5 mg) or an equal volume of matching placebo. Randomisation was done using a computer-generated code with stratification by site. Participants and all study personnel were masked to treatment allocation until the database was locked. Participants were followed up at least every 6 months for the composite primary outcome of stroke, myocardial infarction, or death from cardiovascular or unknown causes. Cognitive function was assessed at baseline and during follow-up using the Montreal Cognitive Assessment (MoCA) and Digit Symbol Substitution Test (DSST). We present here the exploratory primary cognitive outcome, which was the first occurrence of a follow-up score on MoCA or DSST that was 1·5 SDs or more below the baseline mean score in the participant’s country. All analyses were done using an intention-to-treat approach. The REWIND trial is registered with ClinicalTrials.gov, NCT01394952.
Findings |
Between Aug 18, 2011, and Aug 14, 2013, 9901 participants were randomly assigned to either dulaglutide (n=4949) or placebo (n=4952). During median follow-up of 5·4 (IQR 5·1–5·9) years, 8828 participants provided a baseline and one or more follow-up MoCA or DSST scores, of whom 4456 were assigned dulaglutide and 4372 were assigned placebo. The cognitive outcome occurred in 4·05 per 100 patient-years in participants assigned dulaglutide and 4·35 per 100 patient-years in people assigned placebo (hazard ratio [HR] 0·93, 95% CI 0·85–1·02; p=0·11). After post-hoc adjustment for individual standardised baseline scores, the hazard of substantive cognitive impairment was reduced by 14% in those assigned dulaglutide (HR 0·86, 95% CI 0·79–0·95; p=0·0018).
Interpretation |
Long-term treatment with dulaglutide might reduce cognitive impairment in people with type 2 diabetes. Further studies of this drug focused on brain health and cognitive function are clearly indicated.
Funding |
Eli Lilly and Company.
Le texte complet de cet article est disponible en PDF.Plan
Vol 19 - N° 7
P. 582-590 - juillet 2020 Retour au numéro
Article précédent
- Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised controlled trial
- Jay P Mohr, Jessica R Overbey, Andreas Hartmann, Rüdiger von Kummer, Rustam Al-Shahi Salman, Helen Kim, H Bart van der Worp, Michael K Parides, Marco A Stefani, Emmanuel Houdart, Richard Libman, John Pile-Spellman, Kirsty Harkness, Charlotte Cordonnier, Ellen Moquete, Alessandra Biondi, Catharina J M Klijn, Christian Stapf, Alan J Moskowitz, ARUBA co-investigators
- Safety and immunogenicity of the ?-synuclein active immunotherapeutic PD01A in patients with Parkinson’s disease: a randomised, single-blinded, phase 1 trial
- Dieter Volc, Werner Poewe, Alexandra Kutzelnigg, Petra Lührs, Caroline Thun-Hohenstein, Achim Schneeberger, Gergana Galabova, Nour Majbour, Nishant Vaikath, Omar El-Agnaf, Dorian Winter, Eva Mihailovska, Andreas Mairhofer, Carsten Schwenke, Günther Staffler, Rossella Medori
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?